Xencor Inc (XNCR)

NASD · Healthcare · Biotechnology · USA

Xencor Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for treating cancer and autoimmune diseases. The company uses protein engineering to design XmAb candidates with novel mechanisms of action, advancing them through clinical studies. Its portfolio includes bispecific antibodies targeting oncology and autoimmune indications, with marketed medicines developed using its XmAb technologies.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Xencor Inc stock.

Our verdict on XNCR

Overvalued: intrinsic value $4.80 per share, market price $34.50, margin of safety -619.3% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $4.80; the price of $34.50 is 619% above that value.

ETFs with the most weight in XNCR

17 more funds hold it; the full list is part of the paid plan.

More on XNCR

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than XNCR in Biotechnology

98 more in this industry show a wider margin of safety.

Is XNCR undervalued or overvalued?

XNCR is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $4.80; the price of $34.50 is 619% above that value.

What is the intrinsic value of XNCR?

$4.80 per share (as of the 2026-11-17 close), against a market price of $34.50. That is a margin of safety of -619.3%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.